A SINGLE ARM, MULTICENTER, PHASE II, OPEN-LABEL TRIAL TO EVALUATE EFFICACY OF ISATUXIMAB IN PATIENTS WITH MONOCLONAL GAMMOPATHY OF RENAL SIGNIFICANCE
Contact:
NCT Number:
Protocol:
AAAT0761
Study Status:
Active/Enrolling
Population:
Adult
Phase:
II
The purpose of this study is to see whether Isatuximab can help improve kidney function of participants with Monoclonal Gammopathy of Renal Significance (MGRS). Isatuximab is approved by the Food and Drug Administration (FDA) for the treatment of adult patients with multiple myeloma, but it is not approved by the FDA to treatMonoclonal Gammopathy of Renal Significance (MGRS). This means that the use of isatuximab in this study is considered ‘investigational’.
Are you Eligible? (Inclusion Criteria)
- • Are you 18 years of age or older?
- • Do you have persistent renal dysfunction and persistent proteinuria?
- • Have you received a Renal Biopsy with proven diagnosis of MGRS?
Specialty Area(s)
Multiple Myeloma/Amyloidosis
Principal Investigator
Trial Location(s)
CUIMC/Herbert Irving Pavilion
161 Fort Washington Avenue
New York, NY 10032
